Information of Interest
ProMetic would like to bring to your attention recently published data and information that promote our fields of interest and activities.
Posted on June 28, 2013
The “Evaluate 2013 Orphan Drug Report”, published in 2013, outlines that the worldwide orphan drug market is set to reach $127 billion by 2018.
The findings in EvaluatePharma’s report confirm hypotheses that orphan drugs offer a greater return on investment than non-orphan drugs.
Orphan drugs that have been filed for regulatory review or are in phase III trials, provide a 1.7 times greater return on investment than non-orphan drugs. Moreover, phase III development costs for orphan drugs are half of those of non-orphan drugs.
Projected sales are believed to experience a compound annual growth rate of 7.4% for the period between 2012 and 2018, which is nearly double that of the prescription drugs market, excluding generics, and accounts for nearly 16 % of total prescription drug sales.
Amongst the report’s key findings are:
- In 2012, orphan drug sales increased 7.1 percent to $83 billion from 2011.
- Over the same period overall prescription drug sales (excluding generics) declined by 2.1% to $645 billion.
- Novartis has expected sales of $11.8 billion in 2018, maintaining its position as the world’s No. 1 orphan drug company.
- Kyprolis was the most promising new orphan drug in 2012 with U.S. sales expected to reach $897 million in 2017. Kyprolis is a drug from Onyx Pharmaceuticals for multiple myeloma.
- Orphan drug designations in the U.S. fell 7% in 2012, the first decline since 2007.
- Orphan designations in Europe increased 44%, reversing a decline in 2011.
- Of the 43 new drugs approved by the FDA in 2012, 15 were orphan drugs which represented 35% of the industry’s new drug output.
Posted on March 1, 2013
ProMetic Life Sciences Inc. invites you to view the interview of Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. on “Scully, the World Show”. To view the interview, please click here.